Optometrists in St Albans, VT Accepting Medicare

3 Optometrists found. Showing 1 - 3

Dr. Steven John St. Marie, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 128 Fisher Pond Rd, St Albans, VT 05478 Phone: 802-524-9561    Fax: 802-524-6060

John H Johnson, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 156 No Main St, St Albans, VT 05478 Phone: 802-524-3933    Fax: 802-524-2023

Dr. Carl Edward Whitehouse, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 50 Bank St, St Albans, VT 05478 Phone: 802-524-9561    Fax: 802-524-6060

News Archive

CoQ10 may not provide benefits to individuals with Parkinson's disease

These findings contradict results from earlier studies involving a high purity CoQ10 supplement, Vitaline(R) CoQ10. Richard M. Delany, M.D., FACC, and founder of Personalized Preventive Medicine, finds that a closer review of this latest study design reveals important weaknesses, including the use of a short study duration (3 months) and a low daily dosage (300 mg), and failure to use the clinically proven CoQ10 product, Vitaline CoQ10.

Obese pregnant women have greater risk of early and late-onset hypertensive disorders

Pregnant obese women were more at risk of experiencing early and late-onset hypertensive disorders, and that risk progressively increased in women with higher body mass indexes (BMI), according to a study led by researchers at The University of Texas Health Science Center at Houston (UTHealth).

Study: Simple strategies can lead to significant improvements in one-year-olds at risk for ASD

A new study by University of North Carolina at Chapel Hill researchers finds that a collection of simple strategies used by parents can lead to significant improvements in one-year-olds at risk for autism spectrum disorder (ASD).

Researchers discover secret communication hotline between breast cancers and normal cells

Australian researchers have uncovered a secret communication hotline between breast cancers and the normal cells surrounding them. Importantly, the messages sent back and forth between the normal and tumour cells encourage the cancer to survive and to become more aggressive.

Exelixis announces regaining of rights to develop and commercialize XL184

Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.

Read more Medical News

› Verified 8 days ago